Vermani Litika, Samola Winnberg Johanna, Liu Wen, Soller Veronika, Sjödin Tilde, Lindblad Mats, Lindblom Annika
Department of Molecular Medicine and Surgery, Karolinska Institutet, 17176 Stockholm, Sweden.
Division of Surgery, Department of Clinical Science Intervention and Technology (CLINTEC), Karolinska Institutet, 17177 Stockholm, Sweden.
Int J Mol Sci. 2025 Jan 19;26(2):817. doi: 10.3390/ijms26020817.
A previous genome-wide association study (GWAS) in colorectal cancer (CRC) patients with gastric and/or prostate cancer in their families suggested genetic loci with a shared risk for these three cancers. A second haplotype GWAS was undertaken in the same colorectal cancer patients and different controls with the aim of confirming the result and finding novel loci. The haplotype GWAS analysis involved 685 patients with colorectal cancer cases and 1642 healthy controls from Sweden. A logistic regression model was used with a sliding window haplotype approach. Whole-genome and exome sequencing datawere used to find candidate SNPs to be tested in a nested case-control study. In the analysis of 685 colorectal cancer cases and 1642 controls, all ten candidate loci from the previous study were confirmed. Fifty candidate loci were suggested with a -value < 5 × 10 and odds ratios between 1.35-6.52. Two of the 50 loci, on 13q33.3 and 16q23.3, were the same as in the previous study. Whole-genome or exome data from 122 colorectal cancer patients was used to search for candidate variants in these 50 loci. A nested case-control study was performed to test genetic variants at 11 loci in a cohort of 827 familial colorectal cancer and a sub-cohort of 293 familial CRC cases with colorectal, gastric, and/or prostate cancer within their families and 1530 healthy controls. One SNP, rs115943733 on 10q11.21, reached statistical significance (OR = 3.26, = 0.009). Seven SNPs in 4 loci had a higher OR in the smaller cohort compared to the larger study CRC cases. The results in this GWAS gave support for suggested loci with an increased shared risk of CRC, gastric, and/or prostate cancer. Further studies are needed to confirm the shared risk to be able to use this information in cancer prevention.
先前一项针对家族中有胃癌和(或)前列腺癌的结直肠癌(CRC)患者的全基因组关联研究(GWAS)表明,存在对这三种癌症具有共同风险的基因位点。为了证实该结果并发现新的基因位点,对同一批结直肠癌患者和不同的对照组进行了第二项单倍型GWAS。单倍型GWAS分析涉及来自瑞典的685例结直肠癌患者和1642名健康对照。采用逻辑回归模型和滑动窗口单倍型方法。利用全基因组和外显子组测序数据来寻找将在巢式病例对照研究中进行检测的候选单核苷酸多态性(SNP)。在对685例结直肠癌病例和1642名对照的分析中,先前研究中的所有十个候选基因位点均得到证实。提出了50个候选基因位点,其P值<5×10⁻⁸,优势比在1.35至6.52之间。这50个基因位点中的两个,位于13q33.3和16q23.3,与先前研究中的相同。利用122例结直肠癌患者的全基因组或外显子组数据在这50个基因位点中搜索候选变异。在一个由827例家族性结直肠癌患者以及一个包含293例家族性CRC病例(其家族中有结直肠癌、胃癌和(或)前列腺癌)的亚组和1530名健康对照组成的队列中,进行了一项巢式病例对照研究,以检测11个基因位点的基因变异。一个位于10q11.21的SNP,rs115943733,达到了统计学显著性(OR = 3.26,P = 0.009)。与规模较大的结直肠癌病例研究队列相比,4个基因位点中的7个SNP在规模较小的队列中的优势比更高。这项GWAS的结果支持了所提出的对结直肠癌、胃癌和(或)前列腺癌具有增加的共同风险的基因位点。需要进一步的研究来证实这种共同风险,以便能够在癌症预防中利用这些信息。